

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNITED GENE HIGH-TECH GROUP LIMITED

聯合基因科技集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

INSIDE INFORMATION

This announcement is made by United Gene High-Tech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company has expressed intention on 25 February 2014 (after trading hours) to the representative of Extrawell Pharmaceutical Holdings Limited (Stock Code: 858) (“**Extrawell**”), a connected person (as defined under the Listing Rules) of the Company, on a possible acquisition of certain shareholdings of Smart Ascent Limited, as an indirect wholly owned subsidiary of Extrawell and principally engaged in the oral insulin related business (the “**Possible Acquisition**”).

If materialized, the Possible Acquisition may constitute a notifiable transaction for the Company. As at the date of this announcement, the Company has not entered into any written agreement, memorandum of understanding, letter of understanding or intention concerning the Possible Acquisition. Therefore, the Possible Acquisition may or may not materialize.

The Company will make further announcement as and when required in accordance with the Listing Rules.

Shareholders of the Company and potential investors should exercise extreme caution when dealing in the shares of the Company.

By order of the Board
United Gene High-Tech Group Limited
Lee Nga Yan
Executive Director

Hong Kong, 25 February 2014

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Ms. Lee Nga Yan (executive Director), Dr. Guo Yi (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).